Annexon Inc. is a clinical-stage biopharmaceutical company. It engages in developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain and eye. The company's product candidate includes ANX005 and ANX007, which are in clinical stage. Annexon Inc. is based in SAN FRANCISCO, Calif.
| Revenue (Most Recent Fiscal Year) | -- |
| Net Income (Most Recent Fiscal Year) | $-138.20M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.98 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -54.45% |
| Return on Assets (Trailing 12 Months) | -46.56% |
| Current Ratio (Most Recent Fiscal Quarter) | 7.99 |
| Quick Ratio (Most Recent Fiscal Quarter) | 7.99 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $2.22 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.37 |
| Earnings per Share (Most Recent Fiscal Year) | $-1.01 |
| Diluted Earnings per Share (Trailing 12 Months) | $-1.18 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 109.71M |
| Free Float | 96.69M |
| Market Capitalization | $239.18M |
| Average Volume (Last 20 Days) | 1.18M |
| Beta (Past 60 Months) | 1.24 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 11.87% |
| Percentage Held By Institutions (Latest 13F Reports) | -- |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |